Literature DB >> 18176555

Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin.

Aarthi Chandrasekaran1, Aravind Srinivasan, Rahul Raman, Karthik Viswanathan, S Raguram, Terrence M Tumpey, V Sasisekharan, Ram Sasisekharan.   

Abstract

A switch in specificity of avian influenza A viruses' hemagglutinin (HA) from avian-like (alpha2-3 sialylated glycans) to human-like (alpha2-6 sialylated glycans) receptors is believed to be associated with their adaptation to infect humans. We show that a characteristic structural topology--and not the alpha2-6 linkage itself--enables specific binding of HA to alpha2-6 sialylated glycans and that recognition of this topology may be critical for adaptation of HA to bind glycans in the upper respiratory tract of humans. An integrated biochemical, analytical and data mining approach demonstrates that HAs from the human-adapted H1N1 and H3N2 viruses, but not H5N1 (bird flu) viruses, specifically bind to long alpha2-6 sialylated glycans with this topology. This could explain why H5N1 viruses have not yet gained a foothold in the human population. Our findings will enable the development of additional strategies for effective surveillance and potential therapeutic interventions for H5N1 and possibly other influenza A viruses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176555     DOI: 10.1038/nbt1375

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  188 in total

1.  Structural characterization of the hemagglutinin receptor specificity from the 2009 H1N1 influenza pandemic.

Authors:  Rui Xu; Ryan McBride; Corwin M Nycholat; James C Paulson; Ian A Wilson
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  A quantitative structure-activity relationship (QSAR) study on glycan array data to determine the specificities of glycan-binding proteins.

Authors:  Pengfei Xuan; Yuehua Zhang; Tzuen-rong Jeremy Tzeng; Xiu-Feng Wan; Feng Luo
Journal:  Glycobiology       Date:  2011-12-07       Impact factor: 4.313

Review 3.  Glycans as receptors for influenza pathogenesis.

Authors:  Karthik Viswanathan; Aarthi Chandrasekaran; Aravind Srinivasan; Rahul Raman; V Sasisekharan; Ram Sasisekharan
Journal:  Glycoconj J       Date:  2010-08-24       Impact factor: 2.916

Review 4.  The Interaction between Respiratory Pathogens and Mucus.

Authors:  Mark Zanin; Pradyumna Baviskar; Robert Webster; Richard Webby
Journal:  Cell Host Microbe       Date:  2016-02-10       Impact factor: 21.023

5.  Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.

Authors:  Maria Hedlund; Laura M Aschenbrenner; Kellie Jensen; Jeffrey L Larson; Fang Fang
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

6.  Novel fluorescent glycan microarray strategy reveals ligands for galectins.

Authors:  Xuezheng Song; Baoyun Xia; Sean R Stowell; Yi Lasanajak; David F Smith; Richard D Cummings
Journal:  Chem Biol       Date:  2009-01-30

Review 7.  Pathology of human influenza revisited.

Authors:  Thijs Kuiken; Jeffery K Taubenberger
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

8.  A human-infecting H10N8 influenza virus retains a strong preference for avian-type receptors.

Authors:  Heng Zhang; Robert P de Vries; Netanel Tzarum; Xueyong Zhu; Wenli Yu; Ryan McBride; James C Paulson; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

Review 9.  Glycan recognition at the saliva - oral microbiome interface.

Authors:  Benjamin W Cross; Stefan Ruhl
Journal:  Cell Immunol       Date:  2018-08-18       Impact factor: 4.868

10.  Analysis of N-glycans in embryonated chicken egg chorioallantoic and amniotic cells responsible for binding and adaptation of human and avian influenza viruses.

Authors:  Nongluk Sriwilaijaroen; Sachiko Kondo; Hirokazu Yagi; Prapon Wilairat; Hiroaki Hiramatsu; Morihiro Ito; Yasuhiko Ito; Koichi Kato; Yasuo Suzuki
Journal:  Glycoconj J       Date:  2008-10-14       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.